Approaches for generation of anti-leukemia specific T cells.

作者：Jin, Zhenyi; Xu, Ling; Li, Yangqiu

来源：Cell Regeneration, 2018, 7(2): 40-44.

DOI：10.1016/j.cr.2018.09.002

• ACT, adoptive cellular immunotherapy
• APL, promyelocytic leukemia
• Anti-leukemia T cell
• B-ALL, cell acute lymphoblastic leukemia
• CAR-T
• CAR-T, chimeric antigen receptor T cells
• CML, chronic myelogenous leukemia
• CR, complete remission
• CTLs, cytotoxic T cells
• DLI, donor lymphocyte infusion
• FLT3-ITD, FLT3 internal tandem duplication
• GVHD, graft-versus-host disease
• GVL, graft-versus-leukemia
• HLA, human leukocyte antigen
• HPCs, hematopoietic progenitor cells
• IL-2, interleukin-2

As three decades ago, it was reported that adoptive T cell immunotherapy by infusion of autologous tumor infiltrating lymphocytes (TILs) mediated objective cancer regression in patients with metastatic melanoma. A new era of T cell immunotherapy arose since the improvement and clinical use of anti-CD19 chimeric antigen receptor T cells (CAR-T) for the treatment of refractory and relapsed B lymphocyte leukemia. However, several challenges and difficulties remain on the way to reach generic and effective T cell immunotherapy, including lacking a generic method for generating anti-leukemia-specific T cells from every patient. Here, we summarize the current methods of generating anti-leukemia-specific T cells, and the promising approaches in the future.

• 出版日期2018-12
• 单位暨南大学